Ramucirumab, a vascular endothelial growth factor-receptor 2 (VEGFR-2) antibody, as a single agent or in combination with paclitaxel, is included as an option for second-line or subsequent therapy for patients with metastatic disease (Ajani et al. 2019; Fuchs et al. 2014). The gene discussed is KDR; the disease is metastatic neoplasm.